NanoLogix Retains OTC Financial Network for Comprehensive Investor Relations Campaign

NanoLogix, Inc. (OTC Pink Sheets: NNLX), a nano-biotechnology company engaged in the development and commercialization of technologies for the creation of hydrogen bioreactors, today announced that it has retained OTC Financial Network, a division of National Financial Communications Corp. ("NFC"), for a comprehensive investor relations campaign.

Geoffrey Eiten, president of NFC, stated, "NanoLogix is an exciting new issue that is poised to bring to market a vast number of applications within the nano-biotechnology industry. NanoLogix has 31 issued patents with applications in nanotechnology, hydrogen gas production, medical drugs/devices, bio-defense sensors and bioremediation."

Eiten added, "The Company's current focus - converting wastewater into hydrogen to create renewable energy sources - has led to a major agreement with The Erie Wastewater Treatment Plant to convert municipal sewer water into energy. With this initial project underway, NanoLogix stands to market their innovative solutions to other municipalities and corporations seeking to combat skyrocketing oil and gas prices, and reduce their dependency on foreign energy sources."

Mitchell S. Felder, M.D., CEO of NanoLogix, Inc., stated, "Although we are in our early stages of development, we have a strong intellectual property position which we will continue to leverage to expedite the commercialization of new environmentally-friendly processes. We believe now is the right time to tell investors our story. We have entered into a partnership with OTC Financial Network to introduce our company and communicate our key corporate developments to Wall Street, with a near-term goal to becoming a fully reporting company."

About OTC Financial Network

OTC Financial Network is a leading provider of investor relations and financial consulting services and customized, proactive investor relations campaigns to more than 500 small/micro-cap public companies since 1992. A partnership with OTC Financial Network can improve a company's shareholder communications channel, facilitate capital formation opportunities, create an expanding and diversified base of institutional and retail shareholders, and garner financial media coverage. OTC Financial Network is a division of National Financial Communications Corp. based in Needham, MA.

About NanoLogix, Inc.

NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants.

Disclaimer: OTC Financial Network, a division of National Financial Communications Corp., serves as special advisor to NanoLogix, Inc. and has received fees for services, in the amount of ninety thousand dollars for one year of service, payable in restricted shares plus an option to purchase an aggregate of five hundred thousand shares of restricted common stock at an exercise price of forty cents per share, plus expenses, for the creation and distribution of materials. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.